FDA CRL - Tanvex BioPharma USA, Inc

The FDA issued a Complete Response Letter (CRL) to Tanvex BioPharma USA, Inc. for its Biologics License Application (BLA 761266) concerning product TX05. Following a pre-license inspection, the agency identified deficiencies at a manufacturing facility, requiring the company to provide satisfactory responses. Key issues also included an inadequate safety update, necessitating detailed revisions to nonclinical and clinical study data, including comprehensive tabulations of adverse events, reasons for study discontinuations, and a worldwide safety summary. Additionally, the prescribing information and carton/container labeling did not conform to regulatory standards, such as those outlined in 21 CFR 201.56(a) and (d), the Physician Labeling Rule, and the Pregnancy and Lactation Labeling Rule. The proposed proprietary name remains conditionally acceptable pending application approval. Tanvex must address all identified deficiencies and resubmit a complete response within one year. The product cannot be legally marketed until the application receives FDA approval.